FDA releases Biosimilars Action Plan to address competition and affordability for biologics and biosimilar products.
Read more: Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan